Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Therapeutics, Inc. filings document its OSA-focused medical device and healthcare services business, including reported operating results, sleep testing services, the integration of The Sleep Center of Nevada assets and treatment revenue from supported OSA care locations.
The company’s 8-K and related disclosures also cover material financing agreements, warrant exercises, private placements, convertible note terms, resale-registration references, board and committee appointments, annual-report timing and Nasdaq continued-listing compliance tied to stockholders’ equity. These filings describe common stock, warrants and other capital-structure instruments alongside governance and risk-related public-company matters.
Vivos Therapeutics plans a proposed rights offering and intends to file a registration statement with the SEC to support it. The company expects to distribute transferable subscription rights as a dividend to shareholders after the registration statement is declared effective, with the record date set 30 days after effectiveness.
Each right is expected to allow purchase of one common share at the greater of $1.25 per share or 20% above the market price before the record date, with a nine‑month exercise period. Upon exercise, holders are expected to receive a second nine‑month right with an exercise price equal to the greater of $1.75 per share or 40% above the pre‑record‑date market price. Management states the offering is intended to raise additional capital for operations and general corporate purposes.
The rights are intended to be listed for trading, but the transaction is preliminary and subject to many conditions, including SEC effectiveness, exchange rules and any shareholder approvals needed for sufficient authorized shares. Vivos emphasizes there is no assurance the rights offering will be commenced or completed, and any sale would occur only under a prospectus.
Vivos Therapeutics entered into a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, a management services organization supporting sleep apnea and insomnia care for cardiovascular patients in Florida. Vivos expects to own at least 80% of AIM Florida, with SPCVA holding up to 20%, subject to definitive agreements and regulatory requirements.
The plan initially targets Palm Beach County and is based on Vivos’ existing sleep center model. One Sleep Optimization Team is projected to serve about 250 patients per month and generate over $6 million in annual revenue with contribution margins approaching 50% once fully deployed, with potential to add more teams over time.
Vivos Therapeutics has reached a binding Exchange Agreement with Streeterville Capital to exchange up to $4.5 million of its senior secured debt into perpetual, non‑convertible preferred stock and common shares, contingent on completing qualifying equity financings. The Streeterville note, originally $8,225,000, funded the 2025 acquisition of The Sleep Center of Nevada.
If the company raises at least $2.6 million in a first equity tranche and $1.9 million in a second, portions of the note will be exchanged, the note’s maturity will be extended to June 10, 2027, monthly redemptions reduced from $550,000 to $225,000, and redemptions suspended until September 15, 2026.
Separately, Vivos issued an unsecured, zero‑coupon convertible note to V‑Co Investors 4 LLC with a maximum principal of $5,000,000, including a 10% original issuance discount, and has already received $500,000. This note is intended to bridge a planned equity financing of up to $5,500,000, with automatic conversion into the new equity if that financing closes by June 30, 2026.
Vivos also received a Nasdaq notice that its shares traded below the $1.00 minimum bid price from April 23, 2026 to June 4, 2026, triggering a 180‑day cure period to December 2, 2026. The company is currently below Nasdaq’s $2.4 million stockholders’ equity requirement and views the debt‑to‑equity exchange and related equity raise as key parts of its remediation plan, though completion of these transactions is not assured.
Vivos Therapeutics reports first-quarter 2026 revenue of $5.1M, up from $3.0M a year earlier, driven mainly by higher sleep testing and treatment center service revenue. Despite this growth, the company posted a net loss of $7.8M, widening from $3.9M. Operating cash outflow was $6.0M, leaving cash and equivalents at $2.1M against total liabilities of $26.3M and an accumulated deficit of about $133M. Management states that existing cash will not fund operations for the next twelve months, and substantial doubt exists about the company’s ability to continue as a going concern without additional financing. The quarter also reflects integration of the 2025 Sleep Center of Nevada acquisition, which added service revenue but has not yet offset the higher costs and debt taken on for the deal.
Vivos Therapeutics, Inc. notified the SEC it cannot timely file its Form 10-Q for the quarter ended March 31, 2026 and submitted a Form 12b-25 requesting the five-calendar-day extension under Rule 12b-25. The company states its independent auditor and management need additional time to review and consolidate interim financial statements from its SCN acquisition before filing.
The company currently expects to file within the five-day extension. It also reports preliminary operating direction: revenue and gross profit each rose (approximately 70% and 100%, respectively) for the three months ended March 31, 2026 versus the prior-year quarter; SG&A expenses increased about 70%, and net loss is expected to increase. These figures remain under review and may differ in the Form 10-Q.
Vivos Therapeutics, Inc. — Armistice Capital, LLC and Steven Boyd jointly report beneficial ownership of 1,115,859 shares of Common Stock, representing 8.27% of the class as reported with an as‑of date of 03/31/2026. The filing states Armistice Capital exercises shared voting and dispositive power over these shares on behalf of the Master Fund, and the submission is signed by Steven Boyd as Managing Member.
Vivos Therapeutics, Inc. registers 3,964,712 shares of Common Stock for resale, consisting of 1,982,356 shares issuable upon exercise of a five-year Series A Warrant and 1,982,356 shares issuable upon exercise of a 24‑month Series B Warrant. The resale is by a selling stockholder; the company will not receive proceeds from sales but may receive proceeds if the Warrants are exercised for cash.
The prospectus states the Warrants were issued in a January 20, 2026 warrant inducement private placement and that the selling stockholder may sell shares at prevailing market prices, through brokers or negotiated transactions, at its sole discretion. The filing discloses the Company will bear registration expenses and that as of May 7, 2026 the last reported sale price was $0.66 per share; there were 13,714,329 shares outstanding as of that date.
Vivos Therapeutics, Inc. registers 3,964,712 shares of Common Stock issuable upon exercise of two private-placement warrants (1,982,356 shares under a five-year Series A Warrant and 1,982,356 shares under a 24-month Series B Warrant).
This prospectus covers resale by the selling stockholder and states the company will not receive proceeds from sales by the selling stockholder, although the company may receive proceeds if the Warrants are exercised for cash. The filing describes the warrants’ $2.09 exercise price, Nasdaq listing (VVOS), recent last sale price of $0.85 per share (April 28, 2026), and context on the company’s pivot to a medical-provider focused MSO/DSO model and its integration of The Sleep Center of Nevada.
Vivos Therapeutics received a Nasdaq notice on April 17, 2026 that its stockholders’ equity reported in its 2025 annual report does not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity. As of December 31, 2025, the company reported negative stockholders’ equity of about $1.55 million.
Vivos has since completed two equity financings in the first quarter of 2026 for total gross proceeds of $6.8 million, showing it can raise capital, though this alone does not cure the deficiency. The company has until June 1, 2026 to submit a compliance plan and could receive up to October 14, 2026 to regain compliance, but there is no assurance its plan will be accepted or that it will meet the requirement, and a delisting would materially harm its operations and reputation.